Tofacitinib for psoriatic arthritis – second or subsequent line
NIHR HSRIC
Record ID 32016000367
English
Authors' objectives:
Tofacitinib is intended to be used for the treatment of active psoriatic arthritis following the failure of conventional disease-modifying anti-rheumatic drugs (DMARDs) or following failure of biological DMARDs. Tofacitinib is a novel oral janus kinase (JAK) that inhibits JAK1, 2 and 3 in vitro, with functional specificity for JAK1 and 3 thus resulting in the modulation of the immune response. If licensed, tofacitinib will provide an additional oral treatment option for patients with active psoriatic arthritis.
Psoriatic arthritis is an inflammatory arthritis that is associated with psoriasis of the skin and nails and typically develops within 10 years of psoriasis being diagnosed. An estimated 5-10% of people with psoriasis and 25-40% of people with psoriatic arthritis have severe arthritis with progressive joint lesions. Approximately 2.4% of people with psoriatic arthritis are potentially eligible to receive treatment with biological DMARDs.
The clinical management of psoriatic arthritis aims to supress joint, tendon, and entheseal inflammation and reduce functional limitations and joint damage. Current guidelines recommend treatment with one or two conventional DMARDs before proceeding to TNF inhibitors. Tofacitinib is currently in two phase III clinical trials comparing its effect on clinically important changes in arthritis against placebo and adalimumab. These trials are expected to complete in 2016.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/tofacitinib-for-psoriatic-arthritis-second-or-subsequent-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Arthritis, Psoriatic
- Piperidines
- Pyrimidines
- Pyrroles
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.